# SLC38A9 Regulation Affects Hippocampal Neuronal Autophagy: A Potential Alzheimer's Therapeutic Approach by Suppressing Alzheimer's Disease‐Related Protein Deposition

**Authors:** Yixin Chen, Xueying Ji, Jiaxiu Zhao, Zhijun Bao, Yiqin Huang

PMC · DOI: 10.1002/cns.70823 · 2026-03-11

## TL;DR

Reducing SLC38A9 improves autophagy in brain cells, helping clear harmful proteins linked to Alzheimer's and improving memory.

## Contribution

This study identifies SLC38A9 as a novel therapeutic target for Alzheimer's by linking its regulation to autophagy and cognitive function.

## Key findings

- Reducing SLC38A9 promotes autophagic clearance of AD-related proteins in hippocampal neurons.
- SLC38A9 suppression reduces neuronal apoptosis and improves cognitive function in AD models.
- SLC38A9 impairs autophagy, leading to synaptic damage and neuronal loss in Alzheimer's.

## Abstract

Impaired autophagy‐mediated clearance of Alzheimer's disease (AD)‐related proteins is a critical event in AD pathogenesis. SLC38A9, a member of the Solute Carrier 38 family, acts as an arginine sensor and plays an important role in regulating autophagy. Although the activation of autophagy regulated by the SLC38A9 may have a mitigating effect on AD, this aspect still awaits further exploration.

APP/PS1 mouse models and HT22 cells treated with amyloid‐β 25–35 (Aβ25–35) were transduced with vectors to evaluate the effect of SLC38A9 in AD.

We show that decreasing SLC38A9 could promote the hippocampal neuronal autophagic clearance of AD‐related proteins, reduce neuronal apoptosis, and improve cognitive function.

Our results demonstrate SLC38A9 is involved in AD‐related pathology and its cognitive impairment, and may offer new therapeutic targets to AD.

This study demonstrates that SLC38A9 contributes to cognitive impairment in Alzheimer's disease (AD). By impairing autophagic activity in hippocampal neurons, SLC38A9 inhibits the clearance of pathological proteins, thereby exacerbating synaptic damage and neuronal loss. Collectively, these findings identify SLC38A9 as a potential therapeutic target for mitigating cognitive decline in AD, via SLC38A9‐mediated autophagic clearance of pathological proteins..

## Linked entities

- **Genes:** SLC38A9 (solute carrier family 38 member 9) [NCBI Gene 153129]
- **Chemicals:** amyloid-β 25–35 (PubChem CID 10843733)
- **Diseases:** Alzheimer's disease (MONDO:0004975)

## Full-text entities

- **Genes:** Ulk1 (unc-51 like kinase 1) [NCBI Gene 22241] {aka Unc51.1, mKIAA0722}, Rps6kb1 (ribosomal protein S6 kinase B1) [NCBI Gene 72508] {aka 2610318I15Rik, P70S6K1, S6K, S6K-beta-1, S6K1, p70 S6K-alpha}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Dntt (deoxynucleotidyltransferase, terminal) [NCBI Gene 21673] {aka Tdt}, Slc38a9 (solute carrier family 38, member 9) [NCBI Gene 268706] {aka 4833412L08Rik, 6720411P22Rik, 9130023D20Rik, 9430067K09Rik, A730092C09}, Syp (synaptophysin) [NCBI Gene 20977] {aka A230093K24Rik, Syn, p38}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Psen1 (presenilin 1) [NCBI Gene 19164] {aka Ad3h, PS-1, PS1, S182}, Map1lc3a (microtubule-associated protein 1 light chain 3 alpha) [NCBI Gene 66734] {aka 1010001H21Rik, 4922501H04Rik, LC3, LC3a}, SLC38A9 (solute carrier family 38 member 9) [NCBI Gene 153129] {aka SNAT9, URLC11}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, Dlg4 (discs large MAGUK scaffold protein 4) [NCBI Gene 13385] {aka Dlgh4, PSD-95, PSD95, SAP90, SAP90A}, Sqstm1 (sequestosome 1) [NCBI Gene 18412] {aka A170, OSF-6, Osi, STAP, STONE14, p62}
- **Diseases:** AD (MESH:D000544), neurotoxicity (MESH:D020258), infection (MESH:D007239), cancer (MESH:D009369), neurodegeneration (MESH:D019636), visual deficits (MESH:D014786), neurological disorders (MESH:D009461), metabolic disorders (MESH:D008659), Cognitive Impairment (MESH:D003072), memory deficits (MESH:D008569), NFTs (MESH:D055956), synaptic damage (MESH:D012183), Neuronal Damage (MESH:D009410), dementia (MESH:D003704)
- **Chemicals:** xylene (MESH:D014992), dUTP (MESH:C027078), amino acid (MESH:D000596), rapamycin (MESH:D020123), L-arginine (MESH:D001120), A600205 (-), paraffin (MESH:D010232), H&amp;E (MESH:D006371), 3-MA (MESH:C025946), Baf-A1 (MESH:C040929), formalin (MESH:D005557), ethanol (MESH:D000431), DAPI (MESH:C007293), CQ (MESH:D002738), PFA (MESH:C003043)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Lentivirus (genus) [taxon 11646], Homo sapiens (human, species) [taxon 9606], Adeno-associated virus (species) [taxon 272636]
- **Cell lines:** HT22 — Mus musculus (Mouse), Transformed cell line (CVCL_0321), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12977986/full.md

---
Source: https://tomesphere.com/paper/PMC12977986